Pharmacology of Antidepressants—Characteristics of the Ideal Drug

Mayo Clinic Proceedings

Volumn 69, Issue 11, 1994, Pages 1069-1081

  RICHELSON, ELLIOTT ^a  

^a MAYO CLINIC   (United States)

Author keywords

serotonin selective reuptake inhibitors; SSRIs

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AMFEBUTAMONE; AMITRIPTYLINE; CLOMIPRAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HISTAMINE H1 RECEPTOR; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; MUSCARINIC RECEPTOR; NEFAZODONE; NEUROTRANSMITTER UPTAKE INHIBITOR; NORADRENALIN; PAROXETINE; SEROTONIN; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AMNESIA; CLINICAL PHARMACOLOGY; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; FATIGUE; HUMAN; RECEPTOR BLOCKING; REVIEW; SEXUAL DYSFUNCTION; SOMNOLENCE; SYNAPSE; VERTIGO;

EID: 0028099484     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-6196(12)61375-5     Document Type: Review

References (74)

1. The treatment of depressive states with G 22355 (imipramine hydrochloride)
2. Increasing rates of depression
3. Clinical epidemiology of suicide
4. The NIMH Depression Awareness, Recognition, and Treatment Program: structure, aims, and scientific basis
5. Depression, disability days, and days lost from work in a prospective epidemiologic survey
6. The efficacy of antidepressant drugs: a review of research (1958–1972)
7. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects
8. Comorbidity of gastrointestinal complaints, depression, and anxiety in the Epidemiologic Catchment Area (ECA) Study
9. Approach to the patient with mental and emotional complaints
10. Practice guideline for major depressive disorder in adults
11. Venlafaxine: a unique atypical antidepressant [abstract]
12. The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine
13. Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection
14. Fluoxetine kinetics and protein binding in normal and impaired renal function
15. Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly
16. Plasma concentrations of trazodone and I-(3-chlorophenyl)piperazine in man after a single oral dose of trazodone
17. Pharmacokinetics of single oral doses of nortriptyline in depressed elderly hospital patients and young healthy volunteers
18. Pharmacokinetics of the selective serotonin reuptake inhibitors
19. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects
20. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite
21. Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose
22. Antidepressants: a clinical update for medical practitioners
23. Discrepancies between pharmacokinetic studies of amitriptyline
24. Pharmacokinetics and biological effects of nortriptyline in man
25. Tricyclic antidepressants—blood level measurements and clinical outcome: an APA Task Force report
26. Therapeutic drug monitoring: principles and practice
27. Mode of action of antidepressant drugs
28. Antidepressants and brain neurochemistry
29. Neurobiological mechanisms involved in antidepressant therapies
30. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake
31. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
32. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro
33. Binding of antidepressants to human brain receptors: focus on newer generation compounds
34. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled multicenter comparison study in outpatients with major depression
35. Double-blind comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients: clinical aspects
36. Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks: a double-blind comparison of zimeldine, imipramine and placebo
37. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder
38. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings
39. Toxic reaction following the combined administration of fluoxetine and l-tryptophan: five case reports
40. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment
41. Fluoxetine and extrapyramidal side effects [letter]
42. Fluoxetine and anorgasmia [letter]
43. Sertraline and extrapyramidal side effects [letter]
44. Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: relationship with brain concentrations of fluoxetine and norfluoxetine
45. Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions
46. Reversing anorgasmia associated with serotonin uptake inhibitors
47. Histamine as a neuroregulator
48. Histamine receptors in the central nervous system
49. 3-receptors
50. Tricyclic antidepressants: therapy for ulcer and other novel uses
51. Muscarinic receptors: molecular biology and neuropsychopharmacology
52. A cholinergic-adrenergic hypothesis of mania and depression
53. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics
54. Adverse reactions suggesting amoxapine-induced dopamine blockade
55. The effect of amoxapine and imipramine on serum prolactin levels
56. Trimipramine—an atypical neuroleptic?
57. Plasma levels of trazodone: methodology and applications
58. The safety profile of paroxetine
59. Cardiovascular effects of therapeutic doses of tricyclic antidepressants: a review
60. Management of monoamine oxidase inhibitor-associated insomnia with trazodone
61. Review of the cardiovascular effects of heterocyclic antidepressants
62. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes
63. Inhibition by fluoxetine of cytochrome P450 2D6 activity
64. Inhibitors of imipramine metabolism by human liver microsomes
65. Recent pharmacologic advances in antidepressant therapy for the elderly
66. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients
67. Interactions between sertraline and tricyclic antidepressants [letter]
68. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine
69. Desipramine pharmacokinetics with the serotonin reuptake inhibitors (SSRIs), paroxetine or sertraline [abstract]
70. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
71. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia
72. Potential indications for the selective serotonin reuptake inhibitors